Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?

Patients with long-term type 1 and type 2 diabetes mellitus (DM) can develop skeletal complications or “diabetic osteopathy”. These include osteopenia, osteoporosis and an increased incidence of low-stress fractures. In this context, it is important to evaluate whether current anti-diabetic treatmen...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: McCarthy, Antonio Desmond, Cortizo, Ana María, Sedlinsky, Claudia
Formato: Articulo
Lenguaje:Inglés
Publicado: 2016
Materias:
Ciencias Exactas
Ciencias Médicas
Diabetes Mellitus
Osteoporosis
bone fractures
metformin
AMP-activated kinase
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/106633
http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4807302&blobtype=pdf
https://www.wjgnet.com/1948-9358/full/v7/i6/122.htm
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-106633
record_format dspace
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Exactas
Ciencias Médicas
Diabetes Mellitus
Osteoporosis
bone fractures
metformin
AMP-activated kinase
spellingShingle Ciencias Exactas
Ciencias Médicas
Diabetes Mellitus
Osteoporosis
bone fractures
metformin
AMP-activated kinase
McCarthy, Antonio Desmond
Cortizo, Ana María
Sedlinsky, Claudia
Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
topic_facet Ciencias Exactas
Ciencias Médicas
Diabetes Mellitus
Osteoporosis
bone fractures
metformin
AMP-activated kinase
description Patients with long-term type 1 and type 2 diabetes mellitus (DM) can develop skeletal complications or “diabetic osteopathy”. These include osteopenia, osteoporosis and an increased incidence of low-stress fractures. In this context, it is important to evaluate whether current anti-diabetic treatments can secondarily affect bone metabolism. Adenosine monophosphate-activated protein kinase (AMPK) modulates multiple metabolic pathways and acts as a sensor of the cellular energy status; recent evidence suggests a critical role for AMPK in bone homeostasis. In addition, AMPK activation is believed to mediate most clinical effects of the insulin-sensitizer metformin. Over the past decade, several research groups have investigated the effects of metformin on bone, providing a considerable body of pre-clinical (<i>in vitro</i>, <i>ex vivo</i> and <i>in vivo</i>) as well as clinical evidence for an anabolic action of metformin on bone. However, two caveats should be kept in mind when considering metformin treatment for a patient with type 2 DM at risk for diabetic osteopathy. In the first place, met­formin should probably not be considered an anti-osteo­porotic drug; it is an insulin sensitizer with proven macrovascular benefits that can secondarily improve bone metabolism in the context of DM. Secondly, we are still awaiting the results of randomized placebo-controlled studies in humans that evaluate the effects of metformin on bone metabolism as a primary endpoint.
format Articulo
Articulo
author McCarthy, Antonio Desmond
Cortizo, Ana María
Sedlinsky, Claudia
author_facet McCarthy, Antonio Desmond
Cortizo, Ana María
Sedlinsky, Claudia
author_sort McCarthy, Antonio Desmond
title Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
title_short Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
title_full Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
title_fullStr Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
title_full_unstemmed Metformin revisited: Does this regulator of AMP-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
title_sort metformin revisited: does this regulator of amp-activated protein kinase secondarily affect bone metabolism and prevent diabetic osteopathy?
publishDate 2016
url http://sedici.unlp.edu.ar/handle/10915/106633
http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC4807302&blobtype=pdf
https://www.wjgnet.com/1948-9358/full/v7/i6/122.htm
work_keys_str_mv AT mccarthyantoniodesmond metforminrevisiteddoesthisregulatorofampactivatedproteinkinasesecondarilyaffectbonemetabolismandpreventdiabeticosteopathy
AT cortizoanamaria metforminrevisiteddoesthisregulatorofampactivatedproteinkinasesecondarilyaffectbonemetabolismandpreventdiabeticosteopathy
AT sedlinskyclaudia metforminrevisiteddoesthisregulatorofampactivatedproteinkinasesecondarilyaffectbonemetabolismandpreventdiabeticosteopathy
bdutipo_str Repositorios
_version_ 1764820442933100544

Ejemplares similares